- Chief Compliance Officer and VP of Legal Affairs, Arrow Electronics
By 
Kyle Brasseur2022-08-19T15:58:00
The former chief executive officer of Rabobank, N.A. was fined $20,000 by the Office of the Comptroller of the Currency (OCC) last month for his alleged role in obstructing a Bank Secrecy Act (BSA) program examination.
John Ryan, CEO of Rabobank from September 2012 until December 2015, caused a material audit report to not be submitted to the OCC while it was carrying out an investigation at the bank in 2013, the agency alleged. In December 2013, Rabobank agreed to a consent order with the OCC regarding deficiencies in its BSA/anti-money laundering (AML) compliance program. The bank would be fined $50 million by the regulator in 2018 regarding the latter’s findings during that probe.
Ryan’s settlement with the OCC was reached July 28 and announced Thursday.
THIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.
News and analysis for the well-informed compliance or audit exec. Select an option and click continue.
Annual Membership $499 Value offer
Full price one year membership with auto-renewal.
Membership $599
One-year only, no auto-renewal.
The Office of the Comptroller of the Currency dismissed an enforcement action and withdrew a fine against the former chief compliance officer for the now-defunct U.S. branch of Rabobank N.A.
The Financial Accounting Standards Board issued a proposed accounting standards update to improve accounting and disclosures for certain crypto assets.
Rabobank, the second largest bank in the Netherlands, is being investigated by the Dutch Public Prosecution Service for potential violations of the country’s anti-money laundering/countering the financing of terrorism law.
German petrochemical parts supplier Aiotec agreed to pay $14.5 million to settle allegations that it engaged in a four-year conspiracy to dismantle and ship a plastics manufacturing plant owned by a U.S. company to Iran, in violation of U.S. sanctions.
Kiromic BioPharma will pay no fine to the Securities and Exchange Commission after self-reporting that it failed to disclose material information about two cancer drugs to investors.
The U.K. Financial Conduct Authority fined the London branch of Australian-based Macquarie Bank Limited more than 13 million pounds (U.S. $16.3 million) for “serious control failures” that allowed a trader to conceal hundreds of fictitious trades over a 20-month period.
